These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38870368)

  • 41. Botulinum toxin injection for the management of refractory filamentary keratitis.
    Gumus K; Lee S; Yen MT; Pflugfelder SC
    Arch Ophthalmol; 2012 Apr; 130(4):446-50. PubMed ID: 22491914
    [TBL] [Abstract][Full Text] [Related]  

  • 42. OnabotulinumtoxinA in pediatric chronic daily headache.
    Kabbouche M; O'Brien H; Hershey AD
    Curr Neurol Neurosci Rep; 2012 Apr; 12(2):114-7. PubMed ID: 22274570
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of headache relief with cosmetic onabotulinumtoxinA injections.
    Goldman ND; Dorton LH; Marcum KK; Gilbert RM; Sandoval LF
    J Cosmet Dermatol; 2014 Sep; 13(3):224-31. PubMed ID: 25196690
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Post-craniotomy headache: a clinical view with a focus on the persistent form.
    Rocha-Filho PA
    Headache; 2015 May; 55(5):733-8. PubMed ID: 25903913
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Effect of OnabotulinumtoxinA on Aura Frequency and Severity in Patients With Hemiplegic Migraine: Case Series of 11 Patients.
    Chen TY; Garza I; Dodick DW; Robertson CE
    Headache; 2018 Jul; 58(7):973-985. PubMed ID: 29762872
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study.
    Winner PK; Blumenfeld AM; Eross EJ; Orejudos AC; Mirjah DL; Adams AM; Brin MF
    Drug Saf; 2019 Aug; 42(8):1013-1024. PubMed ID: 31102144
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Wear-Off of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review With Analysis of Headache Diaries.
    Ruscheweyh R; Athwal B; Gryglas-Dworak A; Frattale I; Latysheva N; Ornello R; Pozo-Rosich P; Sacco S; Torres Ferrus M; Stark CD
    Headache; 2020 Sep; 60(8):1673-1682. PubMed ID: 32797631
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Effect of OnabotulinumtoxinA on Headache Intensity and Number of Monthly Headache Days in Individuals with Chronic Migraine with Different Levels of Neck Disability.
    Onan D; Arıkan H; Martelletti P
    Toxins (Basel); 2023 Dec; 15(12):. PubMed ID: 38133189
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders.
    Blumenfeld A
    Headache; 2003 Sep; 43(8):853-60. PubMed ID: 12940806
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Short and Mid-Term Predictors of Response to OnabotulinumtoxinA: Real-Life Experience Observational Study.
    Alpuente A; Gallardo VJ; Torres-Ferrús M; Álvarez-Sabin J; Pozo-Rosich P
    Headache; 2020 Apr; 60(4):677-685. PubMed ID: 32086801
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Open label experience of repeated OnabotulinumtoxinA injections towards the sphenopalatine ganglion in patients with chronic cluster headache and chronic migraine.
    Simmonds L; Jamtøy KA; Aschehoug I; Hara S; Meisingset TW; Matharu MS; Tronvik E; Bratbak DF
    Cephalalgia; 2024 Aug; 44(8):3331024241273967. PubMed ID: 39165124
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Open-Label, Multi-Dose, Pilot Safety Study of Injection of OnabotulinumtoxinA Toward the Otic Ganglion for the Treatment of Intractable Chronic Cluster Headache.
    Crespi J; Bratbak D; Dodick DW; Matharu M; Solheim O; Gulati S; Berntsen EM; Tronvik E
    Headache; 2020 Sep; 60(8):1632-1643. PubMed ID: 32583902
    [TBL] [Abstract][Full Text] [Related]  

  • 53. OnabotulinumtoxinA Treatment in Chronic Migraine: Investigation of Its Effects on Disability, Headache and Neck Pain Intensity.
    Onan D; Bentivegna E; Martelletti P
    Toxins (Basel); 2022 Dec; 15(1):. PubMed ID: 36668849
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.
    Blumenfeld AM; Patel AT; Turner IM; Mullin KB; Manack Adams A; Rothrock JF
    J Prim Care Community Health; 2020; 11():2150132720959936. PubMed ID: 32985341
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe.
    Matharu M; Pascual J; Nilsson Remahl I; Straube A; Lum A; Davar G; Odom D; Bennett L; Proctor C; Gutierrez L; Andrews E; Johannes C
    Cephalalgia; 2017 Dec; 37(14):1384-1397. PubMed ID: 28758415
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.
    Silberstein SD; Dodick DW; Aurora SK; Diener HC; DeGryse RE; Lipton RB; Turkel CC
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):996-1001. PubMed ID: 25500317
    [TBL] [Abstract][Full Text] [Related]  

  • 57. OnabotulinumtoxinA in chronic migraine: is the response dose dependent?
    Zandieh A; Cutrer FM
    BMC Neurol; 2022 Jun; 22(1):218. PubMed ID: 35698027
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Single-Group Study on the Effect of OnabotulinumtoxinA in Patients with Chronic Migraine Associated with Medication Overuse Headache: Pain Catastrophizing Plays a Role.
    Grazzi L; Montisano DA; Rizzoli P; Guastafierro E; Marcassoli A; Fornari A; Raggi A
    Toxins (Basel); 2023 Jan; 15(2):. PubMed ID: 36828401
    [TBL] [Abstract][Full Text] [Related]  

  • 59. OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study.
    Boudreau G; Finkelstein I; Graboski C; Ong M; Christie S; Sommer K; Bhogal M; Davidovic G; Becker WJ
    Can J Neurol Sci; 2022 Jul; 49(4):540-552. PubMed ID: 34218836
    [TBL] [Abstract][Full Text] [Related]  

  • 60. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
    Aurora SK; Dodick DW; Turkel CC; DeGryse RE; Silberstein SD; Lipton RB; Diener HC; Brin MF;
    Cephalalgia; 2010 Jul; 30(7):793-803. PubMed ID: 20647170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.